Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.30 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4503382 | 0.82 | TDP1 (0.35) | NPC1RAB9A | |
| SCHEMBL3972509 | 0.81 | CA1 (0.38) | EPHX2 | |
| SCHEMBL4327315 | 0.78 | DDB1 (0.41) | NPC1RAB9A | |
| SCHEMBL1533280 | 0.68 | TDP1 (0.35) | — | |
| SCHEMBL20034254 | 0.68 | EPHX2 (0.36) | ALOX5EPHX2SOS1HSPB1 | |
| SCHEMBL2313060 | 0.66 | — | — | |
| SCHEMBL3971854 | 0.63 | SMN1; SMN2 (0.41) | ALOX5EPHX2 | |
| SCHEMBL31587885 | 0.60 | POLB (0.34) | ALOX5 | |
| SCHEMBL6008271 | 0.60 | PTGS1 (0.35) | ALOX5EPHX2NPC1RAB9A | |
| SCHEMBL2443161 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1412326-B1 | BUTYRIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-08-22 | — | — | EP | disclosed |
| US-7491747-B2 | 4-(Arylthio)- or (4-heteroarylthio)butyric acid derivatives that may be used in the treatment of dyslipidaemia, atherosclerosis and diabetes | MERCK PATENT GMBH (DE) | 2009-02-17 | — | — | US | disclosed |
| US-20050020651-A1 | Butyric acid derivatives | MERCK PATENT GMBH (DE) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020651-A1 | Butyric acid derivatives | GPR119, DBI, GABRB1 | ALOX5 345/4885EPHX2 2148/4885NPC1 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.